Latest Conference Articles

Benjamin Philip Levy, MD, discusses potential methods to optimize molecular testing in lung cancer.

ADCs Showcase Impressive Activity, Second-Line Combos Seek to Raise the Bar in Quest to Target HER2+ NSCLC

February 7th 2022, 10:34pm

Antibody-drug conjugates appear to have the most activity in those with non–small cell lung cancer and HER2 expression.

Repeat Molecular Testing Is Beneficial in EGFR+ NSCLC With Acquired Resistance

February 7th 2022, 9:55pm

Repeat histologic evaluation and molecular testing in patients with EGFR-mutant non–small cell lung cancer who develop acquired resistance to osimertinib can deliver pertinent information that can help guide subsequent treatment decisions.

Abundance of Immunotherapy Combinations Leaves Treatment Selection Unclear in Advanced NSCLC

February 7th 2022, 9:52pm

Although PD-L1 expression and histology served as helpful stratification factors in pivotal trials, the paradigm will need to build out more tailored selection strategies as additional checkpoint inhibitors move through development.

Investigators Set Sights Beyond the PACIFIC Regimen in Unresectable Stage III NSCLC

February 7th 2022, 9:35pm

Concurrent chemoradiation followed by durvalumab has become the standard of care for patients with unresectable stage III non–small cell lung cancer based on the results of the phase 3 PACIFIC trial. However, several strategies are under clinical evaluation to push the paradigm beyond the PACIFIC regimen.

Immunotherapy Advances Drive Progress in Lung Cancer Treatment

February 5th 2022, 11:17pm

In the past 2 years, key data from clinical trials in advanced lung cancer have demonstrated that immunotherapy has expanded the bounds of the armamentarium for the treatment of several lung cancers.

Dr. Basu Roy on Addressing Barriers to Biomarker Testing in Lung Cancer

February 5th 2022, 6:22pm

Upal Basu Roy, PhD, MPH, discusses addressing barriers to biomarker testing in lung cancer.

Dr. Hales on Investigational Treatment Strategies to Build Upon the PACIFIC Trial Results in Stage III NSCLC

February 5th 2022, 6:22pm

Russell Kenneth Hales, MD, discusses investigational treatment strategies that have the potential to build upon the positive results of the phase 3 PACIFIC trial in stage III non–small cell lung cancer.

Neoadjuvant, Adjuvant Immunotherapies Poised to Revolutionize Outcomes in Resectable NSCLC

February 5th 2022, 5:59pm

Surgical resection remains the key treatment modality for early-stage non–small cell lung cancer; however, both systemic adjuvant and neoadjuvant therapeutics are options that have value for patients.

Frontline Maintenance Requires Careful Consideration in Advanced Ovarian Cancer

February 1st 2022, 10:47pm

Alexander Babatunde Olawaiye, MD, discusses factors that influence optimized frontline maintenance therapy in advanced ovarian cancer.

Taking a Look Back at Trials From ASCO GI 2022

February 1st 2022, 2:00pm

Reviewing some of the most talked about abstracts that were presented at the 2022 Gastrointestinal Cancers Symposium.

Secondary Cytoreductive Surgery Requires Careful Selection in Recurrent Ovarian Cancer

January 31st 2022, 10:42pm

Amer Karam, MD, discusses the role of secondary cytoreductive surgery in ovarian cancer and the need for careful patient selection, plus the results from 3 clinical trials and the key differences between these efforts.

Increasing Rate of High-Risk Endometrial Cancer in Black Women Prompts Questions Into Underlying Causes

January 30th 2022, 11:00am

Cortney Eakin, MD, discusses alarming trends in uterine cancer histologies in Black women and some of the potential underlying risk factors at play.

Minimally Invasive Surgery Could Benefit Patients with Advanced Ovarian Cancer

January 28th 2022, 10:07pm

Jubilee Brown, MD, discusses recent developments and upcoming trials exploring minimally invasive surgery in ovarian cancer.

Dr. Casablanca on the Integration of Pembrolizumab in Recurrent or Metastatic Cervical Cancer

January 28th 2022, 9:28pm

Yovanni Casablanca, MD, discusses the integration of pembrolizumab (Keytruda) into the paradigm of recurrent or metastatic cervical cancer.

Immunotherapy Shakes Up Cervical Cancer Treatment Paradigm

January 28th 2022, 6:40pm

Yovanni Casablanca, MD, discusses the incorporation of new treatments into the cervical cancer paradigm and provided insight into the necessity of inclusive research with novel therapies.

Active Clinical Trials of Interest in Endometrial Cancer Explore Novel Up-Front Approaches

January 27th 2022, 10:20pm

Bradley R. Corr, MD, discusses practice-changing developments and active clinical trials that are being done in endometrial cancer.

TST001 Under Evaluation in Locally Advanced or Metastatic Solid Tumors

January 23rd 2022, 11:00am

The safety and tolerability of TST001 is under investigation as a potential treatment option for patients with gastric/gastroesophageal junction cancer and other locally advanced or metastatic solid tumors as part of a phase 1 trial.

Nivolumab Plus mFOLFOX6 and Bevacizumab Misses PFS End Point in mCRC

January 23rd 2022, 12:05am

The addition of nivolumab to mFOLFOX6 and bevacizumab failed to demonstrate a statistically significant improvement in progression-free survival vs mFOLFOX6 and bevacizumab alone in previously untreated patients with metastatic colorectal cancer, according to findings from the phase 2/3 CheckMate 9X8 trial.

Trastuzumab Deruxtecan Demonstrates Sustained Efficacy in HER2+ mCRC

January 22nd 2022, 8:35pm